683 Capital Management’s Palvella Therapeutics PVLA Stock Holding History

683 Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,125	Closed	-$104K	–	334
2022 Q3	$104K	Hold	1,125	–	–	0.01%	156
2022 Q2	$168K	Sell	1,125 -964	-46%	-$176K	0.01%	177
2022 Q1	$506K	Buy	2,089 +964	+86%	+$253K	0.03%	188
2021 Q4	$340K	Hold	1,125	–	–	0.01%	255
2021 Q3	$465K	Hold	1,125	–	–	0.02%	160
2021 Q2	$345K	Hold	1,125	–	–	0.01%	169
2021 Q1	$231K	Hold	1,125	–	–	0.01%	149
2020 Q4	$225K	Hold	1,125	–	–	0.01%	195
2020 Q3	$186K	Hold	1,125	–	–	0.01%	122
2020 Q2	$279K	Hold	1,125	–	–	0.02%	119
2020 Q1	$205K	Hold	1,125	–	–	0.02%	113
2019 Q4	$326K	Sell	1,125 -753	-40%	-$209K	0.04%	87
2019 Q3	$512K	Hold	1,878	–	–	0.06%	94
2019 Q2	$706K	Hold	1,878	–	–	0.06%	108
2019 Q1	$503K	Hold	1,878	–	–	0.05%	106
2018 Q4	$400K	Buy	+1,878	New	+$583K	0.02%	127

Other funds holding PVLA

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

683 Capital Management's PVLA Position: Q4 2022 in Review

683 Capital Management sold out of Palvella Therapeutics (PVLA) in Q4 2022, closing a stake of 1,125 shares — an estimated $104K sold.

683 Capital Management first reported a position in PVLA in Q4 2018 and held it in 16 quarters. The position peaked at $706K in Q2 2019. 63 funds tracked by Wall St. Rank hold PVLA as of Q4 2022.

683 Capital Management reported no remaining Palvella Therapeutics position as of Q4 2022 after selling out during the quarter.
683 Capital Management sold 1,125 Palvella Therapeutics shares in Q4 2022, an estimated $104K.
683 Capital Management first reported a position in Palvella Therapeutics in Q4 2018 and held it in 16 quarters.
683 Capital Management's Palvella Therapeutics position peaked at $706K in Q2 2019.
63 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2022.

Based on 683 Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.